4家江苏生物医药企业获全国大奖

Core Insights - Four Jiangsu enterprises won awards at the 14th China Innovation and Entrepreneurship Competition in the biomedicine national contest, with one Jiangsu company taking the only first prize in the growth enterprise category [1] - The competition featured 228 companies, with 20 from Jiangsu, highlighting the region's strong performance in innovation [1] - A total of 17 Jiangsu companies received the "Excellent Enterprise" title, showcasing the province's competitive edge in the biotech sector [1] Company Highlights - Suzhou Pairui Biotechnology Co., Ltd. won the first prize in the growth enterprise category for its project on "Targeted RNA Modification for Innovative Drug Development," focusing on a small molecule RNA m6A regulator for cancer treatment, currently in phase II clinical trials across 10 hospitals [1] - Suzhou Borui Chuanghe Pharmaceutical Co., Ltd. received the third prize in the growth enterprise category, specializing in radioactive targeted drugs (RDC) for precise tumor diagnosis and treatment, with several proprietary radiopharmaceuticals in clinical stages [1] - Qingyuan Zhixin (Suzhou) Biotechnology Co., Ltd. won the second prize in the startup category for its "AI Manufacturing: Organ Revolution - 3D Organ Full-Stack Solution," which aims to create human-like organs through 3D bioprinting for drug testing and innovative drug development [1] - Ansheng Kangtai Pharmaceutical (Nantong) Co., Ltd. secured the third prize in the startup category with its project targeting acute inflammatory diseases through universal cell products, addressing clinical challenges in genetic diseases and immune rejection [1]